The Effect of Alginate in Gastroesophageal Reflux in Infants

被引:28
作者
Salvatore, Silvia [1 ]
Ripepi, Antonio [1 ]
Huysentruyt, Koen [4 ]
van de Maele, Kristel [4 ]
Nosetti, Luana [1 ]
Agosti, Massimo [2 ,3 ]
Salvatoni, Alessandro [1 ]
Vandenplas, Yvan [4 ]
机构
[1] Univ Insubria, Div Pediat, F Del Ponte Hosp, Varese, Italy
[2] F Del Ponte Hosp, Div Neonatol, Varese, Italy
[3] F Del Ponte Hosp, Neonatal Intens Care Unit, Varese, Italy
[4] Vrije Univ Brussel, Kidz Hlth Castle, UZ Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium
关键词
GUIDELINES JOINT RECOMMENDATIONS; NORTH-AMERICAN SOCIETY; PEDIATRIC GASTROENTEROLOGY; EUROPEAN-SOCIETY; GAVISCON; REPRODUCIBILITY; SIMETHICONE; HEPATOLOGY; NUTRITION; PARAMETER;
D O I
10.1007/s40272-018-0314-0
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundGuidelines are contradictory regarding the use of alginate in infants with persisting gastroesophageal reflux (GER). While The British National Institute for Health and Care (NICE) guidelines consider alginate as a treatment option, the guidelines of the European and North-American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN, NASPGHAN) do not recommend alginates.AimsWe assessed the efficacy of alginate to reduce GER episodes in infants.MethodsIn a prospective, observational study, we consecutively enrolled all infants referred for pH-multiple intraluminal impedance (pH-MII) recording because of persisting GER symptoms not responsive to behavior and dietetic modifications. A 48-h pH-MII was performed in all infants; a baseline recording was performed during the first 24h while magnesium or sodium alginate was administered during the second 24h. The primary endpoint was the difference in the total number of GER episodes per 24h between the baseline day and the second day during which the alginate was administered. The secondary outcome was the difference in symptoms between each period. We also compared other pH-MII data from before and during alginate administration.ResultsWe recruited 43 infants (median age 68days, range 25-306); three pH-MII tracings were excluded because of artifacts. The median number of all MII reflux episodes was significantly reduced during alginate administration (76.0 vs 69.5; p<0.001). Crying-fussiness, cough and regurgitation episodes all significantly improved during alginate administration (p=0.00012; p=0.005 and p=0.04, respectively). The following MII parameters also decreased during the alginate administration: acid (19.0 vs 14.5; p<0.04), non-acid (52.0 vs 49.5; p<0.004), proximal GER episodes (46.0 vs 41.4; p<0.007), and bolus exposure index (1.9 vs 1.6; p=0.002). At least three out of seven pH-MII parameters decreased by>10% during the alginate period in 31/40 infants (77.5%), without a significant difference between magnesium and sodium alginate.ConclusionThese results suggest that alginate significantly decreases the number and extension of both acid and non-acid reflux episodes and associated symptoms in infants.
引用
收藏
页码:575 / 583
页数:9
相关论文
共 31 条
[1]   RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ORAL LIQUID SIMETHICONE PRIOR TO UPPER GASTROINTESTINAL ENDOSCOPY [J].
BERTONI, G ;
GUMINA, C ;
CONIGLIARO, R ;
RICCI, E ;
STAFFETTI, J ;
MORTILLA, MG ;
PACCHIONE, D .
ENDOSCOPY, 1992, 24 (04) :268-270
[2]   Cow's Milk Challenge Increases Weakly Acidic Reflux in Children with Cow's Milk Allergy and Gastroesophageal Reflux Disease [J].
Borrelli, Osvaldo ;
Mancini, Valentina ;
Thapar, Nikhil ;
Giorgio, Valentina ;
Elawad, Mamoun ;
Hill, Susan ;
Shah, Neil ;
Lindley, Keith J. .
JOURNAL OF PEDIATRICS, 2012, 161 (03) :476-+
[3]  
BREUMELHOF R, 1991, AM J GASTROENTEROL, V86, P160
[4]   DOUBLE-BLIND CONTROLLED-STUDY ON THE EFFICACY OF SODIUM ALGINATE (GAVISCON) IN REDUCING GASTROESOPHAGEAL REFLUX ASSESSED BY 24H CONTINUOUS PH MONITORING IN INFANTS AND CHILDREN [J].
BUTS, JP ;
BARUDI, C ;
OTTE, JB .
EUROPEAN JOURNAL OF PEDIATRICS, 1987, 146 (02) :156-158
[5]   Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease [J].
Chiu, C. -T. ;
Hsu, C. -M. ;
Wang, C. -C. ;
Chang, J. -J. ;
Sung, C. -M. ;
Lin, C. -J. ;
Chen, L. -W. ;
Su, M. -Y. ;
Chen, T. -H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (09) :1054-1064
[6]   The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants [J].
Corvaglia, L. ;
Aceti, A. ;
Mariani, E. ;
De Giorgi, M. ;
Capretti, M. G. ;
Faldella, G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (04) :466-470
[7]   Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants [J].
Corvaglia, Luigi ;
Spizzichino, Monica ;
Zama, Daniele ;
Aceti, Arianna ;
Mariani, Elisa ;
Legnani, Elena ;
Faldella, Giacomo .
EARLY HUMAN DEVELOPMENT, 2011, 87 (12) :775-778
[8]   Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study [J].
De Ruigh, A. ;
Roman, S. ;
Chen, J. ;
Pandolfino, J. E. ;
Kahrilas, P. J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (05) :531-537
[9]   Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH [J].
Del Buono, R ;
Wenzl, TG ;
Ball, G ;
Keady, S ;
Thomson, M .
ARCHIVES OF DISEASE IN CHILDHOOD, 2005, 90 (05) :460-463
[10]   A comparative study on the raft chemical properties of various alginate antacid raft-forming products [J].
Dettmar, Peter W. ;
Gil-Gonzalez, Diana ;
Fisher, Jeanine ;
Flint, Lucy ;
Rainforth, Daniel ;
Moreno-Herrera, Antonio ;
Potts, Mark .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2018, 44 (01) :30-39